Maghsoud Dariani, M.Sc., President & CEO, Director
Mr. Dariani has significant experience as an entrepreneurial business leader with a strong background in technology development. Prior to joining Semorex, he was President of Focus Pharmaceuticals, Inc., a private pharmaceutical company, where he managed and guided the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage. Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation where he was responsible for the successful development of the drug Focalin. Mr. Dariani brings together an entrepreneurial capability, strong project management skills, an excellent foundation in science and engineering and most importantly a sound grasp of strategies and business.
Bernard S. Green, PhD., Chief Scientific Officer, Director
Prior to founding Semorex, Dr. Green was a research professor at the Department of Pharmaceutical Chemistry in the Medical School of the Hebrew University of Jerusalem since 1985. He has also been on the Staff and, later, a consultant and adjunct associate professor in the Department of Structural Biology at the Weizmann Institute of Science since 1977. He received his Ph.D. in organic chemistry, with a minor in biochemistry, from the Illinois Institute of Technology, and has held posts at Brandeis University , National Institutes of Health, and the Institute of Biological Research . He has authored some 100 research publications, edited two books and holds six patents. He has expertise in solid state and host-guest chemistry, bio-organic chemistry, and organic photo-chemistry. He is a pioneer in catalytic antibody research and contributed to essentially all aspects of this developing science before applying this body of knowledge to the imprinted polymer field.
Morris Priwler, B.Ec., LL.M., President Semorex Technologies Ltd., Director
Prior to joining Semorex, Mr. Priwler was the founder and managing director of Profile Advanced Technologies Ltd., a company dedicated to commercializing technology in the optics and biotechnology fields. He holds a Masters and Bachelors Degrees in Law and Bachelors Degree in Economics from Monash University , Australia . He practiced law in Australia from 1976 to 1988. From 1988-1990 he established and managed corporate administrative and legal matters for a U.S subsidiary of an Australian public company. Subsequently, he has provided management consulting services to high technology enterprises in Australia , the United States and Israel concerning all aspects of business and strategic development. Mr. Priwler has served on the Board of Directors of several start-up companies, and has been involved as part of the entrepreneurial team in a number of ventures.
Jerome B. Zeldis, M.D., Ph.D., Director
Dr. Zeldis is currently the chief medical officer and vice president for medical affairs at Celgene Corporation. He is also currently a clinical associate professor at the Robert Woods Johnson School of Medicine. Prior to joining Celgene, Dr. Zeldis was associate director of clinical research and director of medical development at Sandoz Research Institute and Janssen Pharmaceutical Research Institute, respectively. He holds an A.B. and M.Sc. in molecular biology from Brown University, and earned a M.Phil, a M.D. and a Ph.D. in molecular biophysics and biochemistry from Yale University. He completed an internship and residency in internal medicine at the UCLA Center for the Health Sciences and was a clinical and research fellow in gastroenterology at Massachusetts General Hospital and Harvard Medical School.
Executive Directors: Maghsoud Dariani; Bernard S. Green; Morris Priwler
Scientific Advisory Board
Professor Kenneth Anderson, M.D.
Dr. Kenneth Anderson, is Professor of Medicine at the Harvard Medical School, Chief of Division of Hematological Neoplasia, Director of Jerome Lipper Multiple Myeloma Center, Vice Chair of the Joint Program in Transfusion Medicine, and an oncology physician at the Dana-Farber Cancer Institute.
Professor Günter Wulff, Ph.D.
Dr. Günter Wulff is a Professor emeritus at the University of Düsseldorf where he held the chair of Organic and Macromolecular Chemistry prior to retirement. His research interests include the synthesis of polymers with enzyme-analogous properties through imprinting with template molecules and the synthesis of specialty polymers. Dr. Wulff has served on many select national and international chemical committees and has lectured worldwide. The field of Molecularly Imprinted Polymers was initiated by Dr. Wulff in 1972.
Late, Professor Joshua Lederberg, Ph.D., Nobel Laureate
Rina Arad -Yellin, Ph.D., Senior Research Chemist and Lab Manager
Dr. Rina Arad-Yellin is in Semorex for 14 years. Prior to joining Semorex, she was a senior researcher and laboratory manager at the Department of Organic Chemistry of the Weizmann Institute of Science for more than 20 years. She received her Ph.D. from the Weizmann Institute of Science and worked for DuPont de Nemours, Bell Laboratories and Hoffman-La-Roche. Dr. Arad-Yellin is a co-author of 70 research publications, and 5 patents. she has lectured in many national and international meetings and contributed more than 50 abstracts to scientific conferences. Her major research interests are focused in the field of synthesis and study of new compounds.
Dr. David Dweck, Ph.D., Biologist, Senior Researcher
Dr. Dweck received his PhD in 2008 from the University of Miami, Miller School of Medicine, Miami, Florida. He was a postdoctoral associate in the Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine (2009-2012) and in the Department of Biomedical Sciences, Florida State University College of Medicine (2013-2014). His research interests were focused in the development of high throughput screening assays to identify compounds that alter the calcium regulation of cardiac muscle contraction and the development of biochemical assays to screen millions of compounds for effects on cardiac muscle contraction and dynamics.
David is co-author of 13 research publications and a patent; he has lectured in many national meetings; and also lectured to graduate and medical students on cardiovascular diseases, pharmacology, and therapeutics in University of Miami, Miller School of Medicine and Florida State University College of Medicine (2009-2013).
David joined Semorex Technologies in 2014 and is advancing the development of effective protein imprinted polymers.